newsfilter
← Latest News
Business Wire·

Silence Therapeutics Highlights Recent Business Achievements and Reports First Quarter 2026 Financial Results

Phase 2 SANRECO trial of divesiran, a first-in-class siRNA for polycythemia vera (PV), on-track for topline results in August 2026 Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), a global